Cart
sales@molnova.com
BMP agonist 2
CAS No. 1438900-88-9
BMP agonist 2( —— )
Catalog No. M37562 CAS No. 1438900-88-9
BMP agonist 2 has up-regulated bone morphogenetic protein BMP-2 expression activity in vivo and anti-osteoporosis effects, and also has ameliorated the symptoms of osteoporosis in SAMP6 mice.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 123 | In Stock |
|
| 10MG | 188 | In Stock |
|
| 25MG | 395 | In Stock |
|
| 50MG | 612 | In Stock |
|
| 100MG | 918 | In Stock |
|
| 200MG | 1283 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBMP agonist 2
-
NoteResearch use only, not for human use.
-
Brief DescriptionBMP agonist 2 has up-regulated bone morphogenetic protein BMP-2 expression activity in vivo and anti-osteoporosis effects, and also has ameliorated the symptoms of osteoporosis in SAMP6 mice.
-
DescriptionBMP agonist 2 has up-regulated bone morphogenetic protein BMP-2 expression activity in vivo and anti-osteoporosis effects, and also has ameliorated the symptoms of osteoporosis in SAMP6 mice.BMP agonist 2 is an osteoinductive cytokine that promotes the production of bone tissue, and can be used in the study of senile osteoporosis (SOP).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1438900-88-9
-
Formula Weight305.33
-
Molecular FormulaC16H19NO5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(OCCN1CCOCC1)C=2OC=3C=C(OC)C=CC3C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
[Val5] Angiotensin I...
[Val5] Angiotensin I, human
-
Ameltolide
Ameltolide is an anticonvulsant agent. It has been shown to be effective at inhibiting seizures in animal models.
-
PF-04937319
PF-04937319 is an activator of glucokinase (EC50 =154.4 ?μM). PF-04937319 maintains glucose-lowering efficacy while mitigating the risk of hypoglycemia observed with many other glucokinase activators. PF-04937319 can be used in research on the treatment of type 2 diabetes mellitus.
